The Reaction Oncology Platform
The Reaction Oncology Platform is Reaction Biology’s answer to the growing demand of integrated drug discovery needs to find new cures in the fight against cancer. Our broad portfolio and global network of partners enable us to provide end-to-end service for the discovery of new cancer therapeutics by holding true to our values: quality data, quality support.
20 years of experience in creating new small molecules against cancer enable a science-driven approach warranting high success rates. Your team will consist of our top-level scientists available for direct communication to provide innovative research solutions custom-tailored to your project.
As a medium-sized CRO with 120 employees, we are large enough to provide consistent end-to-end solutions and small enough to welcome projects of any size. We care about your research projects because your work and our relationship are important to us.
Why partner with us?
Comprehensive: A broad portfolio of 2000+ assays gives your project a head start.
Collaborative: Our clients work directly with our team of top-level scientists. A scientific program manager facilitates the progress of the project, ensures timelines are met, and assists with the communication between teams.
Consistent: Full coverage of drug efficacy testing capabilities, including biochemical, biophysical, cellular, and in vivo models, ensuring data consistency within your program.
Cross-Disciplinary: We work with the best partners providing medicinal chemistry support as well as ADME-Tox and cardiac safety services. All under one single contract.
Client Service: We pride ourselves on responsive customer service - providing continuity with a dedicated senior scientist team.
Our goal is the creation of potent drug candidates to meet the needs of tomorrow's cancer patients.
The Reaction Oncology Platform integrates various aspects of drug discovery into one program. What makes a successful program?
The ability for informed decision-making by providing potency and functional data allows insight into the mechanism of compound-target interaction.
Cancer is an incredibly diverse disease, with many patients often not responding to new drugs. Finding predictive biomarkers ensures that drug testing is performed in cell and animal models that work and paves the way for patient stratification during the clinical phase.
The safety and bioavailability of new drug candidates are vital for progressing into the regulatory phase. Therefore, our full coverage of cardiac liability assays and partnership with an expert ADME-tox firm ensures the creation of drugs with favorable pharmacologic and toxicologic profiles.
- Your team comprises our top-level scientists, including chemists, biologists, and pharmacologists.
- One scientific program manager will advance your project through the various discovery phases and manage timelines and expectations.
- Our scientific leaders are available for direct consultation already in the planning phase of new projects.